Prevalence of PD-L1 Expression in NSCLC

75% of patients icon
75% of patients icon

EGFRm tumors may also overexpress PD-L16-8

Based on meta-analyses

For EGFRm NSCLC, PD-L1 expression ranges from6-8

 

31% to 37% icon
31% to 37% icon

For EGFR WT NSCLC, PD-L1 expression ranges from 30% to 44%.6-8

In newly diagnosed patients with mNSCLC, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend PD-1/ PD-L1 inhibitor therapy for patients with PD-L1 expression and negative or unknown EGFR, BRAF, ALK, or ROS1.9

In newly diagnosed patients with mNSCLC, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend PD-1/ PD-L1 inhibitor therapy for patients with PD-L1 expression and negative or unknown EGFR, BRAF, ALK, or ROS1.9

*PD-L1 scoring criteria and assays used to determine expression level varied across trials.
Data are derived from 3 meta-analyses investigating the relationship between PD-L1 expression and clinicopathological features and driver mutations in lung cancer patients. There was overlap of trials included in each meta-analysis. PD-L1 scoring criteria and assays used to determine expression level varied across trials.

ALK, anaplastic lymphoma kinase; BRAF, v-Raf murine sarcoma viral oncogene homolog B; EGFR, epidermal growth factor receptor; EGFRm, EGFR­ mutation–positive; mNSCLC, metastatic non–small cell lung cancer; NCCN, National Comprehensive Cancer Network; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; ROS1, ROS proto-oncogene 1, receptor tyrosine kinase; TC, tumor cell; TPS, tumor proportion score; WT, wild type.

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

References: 1. Borghaei H et al. N Engl J Med. 2015;373(17):1627-1639. 2. Garon EB et al. N Engl J Med. 2015;372(21):2018-2028. 3. Herbst RS et al. Nature. 2014;515(7528):563-567. 4. Herbst RS et al. Lancet. 2016;387(10027):1540-1550. 5. Fehrenbacher L et al; POPLAR Study Group. Lancet. 2016;387(10030):1837-1846. 6. Li J et al. J Thorac Dis. 2017;9(8):2560-2571. 7. Yang H et al. Oncotarget. 2017;8(14):23517-23528. 8. Zhang M et al. Sci Rep. 2017;7(1):10255. 9. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non–Small Cell Lung Cancer V6.2018. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed September 27, 2018. To view the most recent and complete version of the guidelines, go online to NCCN.org.